

Express Mail Label No.: EF17305323US

Date of Deposit: September 20, 2001

Attorney Docket No. CST/NEB-138 CIP



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
SEP 25 2001  
TECH CENTER 1600/2900

APPLICANTS: Comb *et al.*  
ASSIGNEE: CELL SIGNALING TECHNOLOGY, INC.  
SERIAL NUMBER: 09/535,364 EXAMINER: T. Wessendorf  
FILING DATE: March 24, 2000 ART UNIT: 1627  
FOR: PRODUCTION OF MOTIF-SPECIFIC AND CONTEXT-INDEPENDENT ANTIBODIES  
USING PEPTIDE LIBRARIES AS ANTIGENS

September 20, 2001  
Beverly, Massachusetts

Assistant Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO NOTICE TO COMPLY WITH  
SEQUENCE LISTING REQUIREMENTS**

The present papers are filed in response to the June 19, 2001, Notice to Comply With Sequence Listing Requirements received in the above-identified application. Accordingly, Applicants submit herewith: (1) A courtesy copy of the Submission of Paper Copy and Computer Readable Copy of Sequence Listing being simulataneously filed with the Sequence Group ("Box Sequence"); (2) a Preliminary Amendment; and (3) a Petition for a three (3) month extension of time along with the required fee (small entity) under 37 C.F.R. §1.17(a)(3). With the extension, these papers are due October 19, 2001.

Applicants believe no further fees are due in connection with the present filing. However, the Commissioner is hereby authorized to charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-1774, Ref. No. CST-138 CIP.

Respectfully submitted,

James Gregory Cullem, Reg. No. 43,569  
Intellectual Property Counsel  
CELL SIGNALING TECHNOLOGY, INC.  
166B Cummings Center  
Beverly, MA 01915  
(978) 867-2311

**COPY**

RECEIVED

SEP 25 2001

TECH CENTER 1600/2900 09/5353  
Application No.: 087

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- SEP 20 2001  
PATENT OFFICE
1. This application clearly falls to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
  - ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
  - ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
  - ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
  - ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
  - ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
  - ☒ 7. Other: Applicant should follow the format of the attached sample statement to request that the CRF filed in the parent application be used to create a CRF in this application.

**Applicant Must Provide:**

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☐ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

Express Mail Label No. EF1770 323US

Date of Deposit: September 20, 2001

Attorney Docket No. CST/NEB-138 GP

09-21-01

1627\$  
RECEIVED  
SEP 25 2001  
TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Comb *et al.*  
ASSIGNEE: CELL SIGNALING TECHNOLOGY, INC.  
SERIAL NUMBER: 09/535,364 EXAMINER: T. Wessendorf  
FILING DATE: March 24, 2000 ART UNIT: 1627  
FOR: PRODUCTION OF MOTIF-SPECIFIC AND CONTEXT-INDEPENDENT ANTIBODIES  
USING PEPTIDE LIBRARIES AS ANTIGENS

September 20, 2001  
Beverly, Massachusetts

Assistant Commissioner for Patents  
Washington, D.C. 20231

Attached hereto for filing in the above-identified patent application are:

- ☒ Transmittal Letter to the U.S. Receiving Office (1 page);
- ☒ Response to Notice to Comply With Sequence Listing Requirements (1 page);
- ☒ Copy of Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 page);
- ☒ Submission of Paper Copy and/or Computer-Readable Copy of Sequence Listing for Invention Containing nucleotide and/or Amino Acid Sequence (2 pages);
- ☒ Preliminary Amendment (3 pages) w/ Marked-up Pages (6 pages);
- ☒ Petition for Extension of Time (1 page; in duplicate);
- ☒ Paper Copy of Sequence Listing (33 pages);
- ☒ Change of Correspondence Address (1 pages);
- ☒ Duplicate Copy of this Transmittal Letter (1 pg.);
- ☒ Check # 20181 in the amount of \$445.00
- ☒ Return Postcard.

Respectfully submitted,

James Gregory Cullem, Reg. No. 43,569  
Intellectual Property Counsel  
c/o CELL SIGNALING TECHNOLOGY, INC.  
166B Cummings Center  
Beverly, Massachusetts 01915  
Tel: (978) 867-2311  
Fax: (978) 867-2400